Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03790111 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer
A Phase 2 study, sponsored by TerSera Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT03790111 is a Phase 2 study that was terminated before completion, run by TerSera Therapeutics. The registered enrollment target is 53 participants.
The verdict
NCT03790111, a Phase 2 study, was terminated before completion, sponsored by TerSera Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
A Phase 2, multicenter, open-label, 2-stage study to assess the safety, tolerability, and efficacy of XERMELO in combination with first-line (1L) therapy (cisplatin \[cis\] plus gemcitabine \[gem\])
Interventions
- DRUG telotristat ethyl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2019-03-13 |
| Est. Completion | 2022-01-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03790111
The ClinicalTrials.gov registry entry for NCT03790111 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TerSera Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which telotristat ethyl is the first listed.
NCT03790111 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03790111 about?
NCT03790111 is a clinical study titled "A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer". A Phase 2, multicenter, open-label, 2-stage study to assess the safety, tolerability, and efficacy of XERMELO in combination with first-line (1L) therapy (cisplatin \[cis\] plus gemcitabine \[gem\])
What is the current status of trial NCT03790111?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2019-03-13. Estimated completion is 2022-01-13.
What interventions are being tested in trial NCT03790111?
The interventions under investigation include: telotristat ethyl (DRUG).
Who is sponsoring clinical trial NCT03790111?
This trial is sponsored by TerSera Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.